Microbot Medical announces that Brigham and Women’s Hospital will participate as a clinical trial site for the pivotal human clinical trial as part of its Investigational Device Exemption application for its LIBERTY Endovascular Robotic Surgical System. Dr. Dmitry Rabkin, MD, PhD has been selected as principal investigator at BWH. BWH has completed the Site Initiation Visit, during which BWH clinical staff was trained on the clinical study protocols. In addition, a shipment of LIBERTY investigational units arrived at BWH this week for the clinical trial.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBOT:
- Microbot Medical Announces Brigham and Women’s Hospital as a Site for its Pivotal Human Clinical Trial
- Microbot Medical files to sell 3.21M shares of common stock for holders
- Microbot Medical Announces Closing of $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
- Microbot Medical Announces $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
- Microbot Medical reports $2.35M registered direct offering priced at-the-market